دورية أكاديمية
Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis.
| العنوان: | Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. |
|---|---|
| المؤلفون: | Scolnik M; Rheumatology Unit, Department of Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Electronic address: marina.scolnik@hospitalitaliano.org.ar., Brance ML; School of Medicine, National Rosario University, Santa Fe, Argentina., Fernández-Ávila DG; Rheumatology Division, Pontificia Universidad Javeriana, Bogotá, Colombia., Inoue Sato E; Medicine Department, Universidade Federal de São Paulo, São Paulo, Brazil., de Souza AWS; Medicine Department, Universidade Federal de São Paulo, São Paulo, Brazil., Magri SJ; Rheumatology Unit, Hospital Italiano de La Plata, La Plata, Argentina., Saldarriaga-Rivera LM; Rheumatology Unit, Hospital Universitario San Jorge, Pereira, Colombia., Ugarte-Gil MF; School of Medicine, Universidad Cientifica del Sur, Lima, Peru., Flores-Suarez LF; Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico., Babini A; Rheumatology Unit, Hospital Italiano de Cordoba, Cordoba, Argentina., Zamora NV; Rheumatology Unit, Hospital San Jose, Pergamino, Argentina., Acosta Felquer ML; Rheumatology Unit, Department of Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Vergara F; Immunology Unit, Hospital Central, Mendoza, Argentina., Carlevaris L; Rheumatology Unit, Hospital Privado de Mendoza, Mendoza, Argentina., Scarafia S; Rheumatology Unit, Hospital Municipal San Cayetano, Virreyes, Argentina., Soriano Guppy ER; Rheumatology Unit, Department of Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Unizony S; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: sunizony@mgh.harvard.edu. |
| مؤلفون مشاركون: | Pan American League of Associations for Rheumatology (PANLAR) |
| المصدر: | The Lancet. Rheumatology [Lancet Rheumatol] 2022 Dec; Vol. 4 (12), pp. e864-e872. Date of Electronic Publication: 2022 Oct 22. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Elsevier Ltd., [2019]- |
| مواضيع طبية MeSH: | Giant Cell Arteritis*/drug therapy , Rheumatology*, Humans ; Argentina ; Aspirin ; Brazil ; Glucocorticoids/therapeutic use |
| مستخلص: | Considerable variability exists in the way that health-care providers treat patients with giant cell arteritis in Latin America, with patients commonly exposed to excessive amounts of glucocorticoids. In addition, large health disparities prevail in this region due to socioeconomic factors, which influence access to care, including biological treatments. For these reasons, the Pan American League of Associations for Rheumatology developed the first evidence-based giant cell arteritis treatment guidelines tailored for Latin America. A panel of vasculitis experts from Mexico, Colombia, Peru, Brazil, and Argentina generated clinically meaningful questions related to the treatment of giant cell arteritis in the population, intervention, comparator, and outcome (PICO) format. Following the grading of recommendations, assessment, development, and evaluation methodology, a team of methodologists did a systematic literature search, extracted and summarised the effects of the interventions, and graded the quality of the evidence. The panel of vasculitis experts voted on each PICO question and made recommendations, which required at least 70% agreement among the voting members to be included in the guidelines. Nine recommendations and one expert opinion statement for the treatment of giant cell arteritis were developed considering the most up-to-date evidence and the socioeconomic characteristics of Latin America. These recommendations include guidance for the use of glucocorticoids, tocilizumab, methotrexate, and aspirin for patients with giant cell arteritis. Competing Interests: Declaration of interests Several authors of these guidelines, including voting members, have interacted with the pharmaceutical industry including the manufacturers of some of the drugs mentioned in these recommendations. However, none of the authors received any support or fee directly or indirectly related to or influencing the development of these guidelines. DGF-A, MLB, and ERSG are part of PANLAR committees and were involved in the critical review and editing of the manuscript. No other PANLAR committee member was involved in the writing of the manuscript. NVZ, MLAF, FV, LC, and SS received financial support from PANLAR. MS, AB, SJM, EIS, AWSdS, LMS-R, MFU-G, LFF-S, and SU did not receive financial support for this project from any entity. In addition, MS reports speaker fees from Bristol Myers Squibb, GlaxoSmithKline, Janssen, Elli Lilly, Pfizer, and Roche, and travel grants from Janssen, Pfizer, Roche, and AbbVie, all outside the submitted work. DGF-A reports consulting fees from AbbVie, speaker fees from Amgen, Janssen, Novartis, Elli Lilly, and Pfizer; travel grants from Janssen; and research grants from Pfizer, all outside the submitted work. AB reports speaker fees AbbVie, GlaxoSmithKline, Janssen, Pfizer, Boehringer Ingelheim, Bristol Myers Squibb, all outside the submitted work. SJM reports speaker fees from Roche, Janssen, and GlaxoSmithKline, and travel grants from Roche, Pfizer, AbbVie, Janssen, and Sandoz, all outside the submitted work. EIS reports consulting fees from Janssen outside the submitted work. LMS-R reports consulting fees from Roche, Novartis, and Janssen, and travel grants from Janssen and Novartis, all outside the submitted work. MFU-G reports travel grants from Pfizer and AbbVie, and research grants from Janssen, all outside the submitted work. ERSG reports consulting fees from AbbVie, Amgen, Janssen, Elli Lilly, Novartis, Pfizer, and Sandoz; speaker fees from AbbVie, Amgen, Janssen, Elli Lilly, Novartis, Pfizer, and Sandoz; travel grants from AbbVie; and research grants from Amgen, Novartis, Janssen, and Pfizer, all outside the submitted work. SU reports consulting fees from Kiniksa, Sanofi, GlaxoSmithKline, and Janssen, and research grants from Genentech and Janssen, all outside the submitted work. All other authors declare no competing interests. (Copyright © 2022 Elsevier Ltd. All rights reserved.) |
| المشرفين على المادة: | R16CO5Y76E (Aspirin) 0 (Glucocorticoids) |
| تواريخ الأحداث: | Date Created: 20240123 Date Completed: 20240124 Latest Revision: 20240124 |
| رمز التحديث: | 20240124 |
| DOI: | 10.1016/S2665-9913(22)00260-0 |
| PMID: | 38261393 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2665-9913 |
|---|---|
| DOI: | 10.1016/S2665-9913(22)00260-0 |